vs
CAVCO INDUSTRIES, INC.（CVCO）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是CAVCO INDUSTRIES, INC.的1.1倍（$622.0M vs $581.0M），Royalty Pharma plc净利率更高（34.4% vs 7.6%，领先26.9%），CAVCO INDUSTRIES, INC.同比增速更快（11.3% vs 4.8%），过去两年CAVCO INDUSTRIES, INC.的营收复合增速更高（17.6% vs 4.6%）
Cavco工业是总部位于美国亚利桑那州凤凰城的制造企业，主营模块化住宅、休闲房车、度假木屋及预制房屋产品，在美国各地布局有完善的制造工厂与零售门店网络，可满足多元居住及休闲场景的使用需求。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CVCO vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.1倍
$581.0M
营收增速更快
CVCO
高出6.5%
4.8%
净利率更高
RPRX
高出26.9%
7.6%
两年增速更快
CVCO
近两年复合增速
4.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $581.0M | $622.0M |
| 净利润 | $44.1M | $214.2M |
| 毛利率 | 23.4% | — |
| 营业利润率 | 9.4% | 62.4% |
| 净利率 | 7.6% | 34.4% |
| 营收同比 | 11.3% | 4.8% |
| 净利润同比 | -22.0% | 2.9% |
| 每股收益（稀释后） | $5.58 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVCORPRX
| Q4 25 | $581.0M | $622.0M | ||
| Q3 25 | $556.5M | $609.3M | ||
| Q2 25 | $556.9M | $578.7M | ||
| Q1 25 | $508.4M | $568.2M | ||
| Q4 24 | $522.0M | $593.6M | ||
| Q3 24 | $507.5M | $564.7M | ||
| Q2 24 | $477.6M | $537.3M | ||
| Q1 24 | $420.1M | $568.0M |
净利润CVCORPRX
| Q4 25 | $44.1M | $214.2M | ||
| Q3 25 | $52.4M | $288.2M | ||
| Q2 25 | $51.6M | $30.2M | ||
| Q1 25 | $36.3M | $238.3M | ||
| Q4 24 | $56.5M | $208.2M | ||
| Q3 24 | $43.8M | $544.0M | ||
| Q2 24 | $34.4M | $102.0M | ||
| Q1 24 | $33.9M | $4.8M |
毛利率CVCORPRX
| Q4 25 | 23.4% | — | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 22.8% | — | ||
| Q4 24 | 24.9% | — | ||
| Q3 24 | 22.9% | — | ||
| Q2 24 | 21.7% | — | ||
| Q1 24 | 23.6% | — |
营业利润率CVCORPRX
| Q4 25 | 9.4% | 62.4% | ||
| Q3 25 | 11.2% | 70.1% | ||
| Q2 25 | 10.8% | 36.3% | ||
| Q1 25 | 7.6% | 94.0% | ||
| Q4 24 | 12.3% | 60.9% | ||
| Q3 24 | 9.7% | — | ||
| Q2 24 | 8.1% | 50.2% | ||
| Q1 24 | 8.9% | -13.0% |
净利率CVCORPRX
| Q4 25 | 7.6% | 34.4% | ||
| Q3 25 | 9.4% | 47.3% | ||
| Q2 25 | 9.3% | 5.2% | ||
| Q1 25 | 7.1% | 41.9% | ||
| Q4 24 | 10.8% | 35.1% | ||
| Q3 24 | 8.6% | 96.3% | ||
| Q2 24 | 7.2% | 19.0% | ||
| Q1 24 | 8.1% | 0.8% |
每股收益（稀释后）CVCORPRX
| Q4 25 | $5.58 | $0.49 | ||
| Q3 25 | $6.55 | $0.67 | ||
| Q2 25 | $6.42 | $0.07 | ||
| Q1 25 | $4.42 | $0.55 | ||
| Q4 24 | $6.90 | $0.46 | ||
| Q3 24 | $5.28 | $1.21 | ||
| Q2 24 | $4.11 | $0.23 | ||
| Q1 24 | $4.05 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $241.9M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.1B | $9.7B |
| 总资产 | $1.5B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CVCORPRX
| Q4 25 | $241.9M | $618.7M | ||
| Q3 25 | $391.8M | $938.9M | ||
| Q2 25 | $362.4M | $631.9M | ||
| Q1 25 | $376.1M | $1.1B | ||
| Q4 24 | $378.9M | $929.0M | ||
| Q3 24 | $388.7M | $950.1M | ||
| Q2 24 | $380.0M | $1.8B | ||
| Q1 24 | $371.0M | $843.0M |
总债务CVCORPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CVCORPRX
| Q4 25 | $1.1B | $9.7B | ||
| Q3 25 | $1.1B | $9.6B | ||
| Q2 25 | $1.1B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $1.0B | $10.3B | ||
| Q2 24 | $1.0B | $9.8B | ||
| Q1 24 | $1.0B | $9.9B |
总资产CVCORPRX
| Q4 25 | $1.5B | $19.6B | ||
| Q3 25 | $1.4B | $19.3B | ||
| Q2 25 | $1.4B | $18.3B | ||
| Q1 25 | $1.4B | $17.6B | ||
| Q4 24 | $1.4B | $18.2B | ||
| Q3 24 | $1.4B | $18.0B | ||
| Q2 24 | $1.4B | $17.7B | ||
| Q1 24 | $1.4B | $16.1B |
负债/权益比CVCORPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $57.6M | — |
| 自由现金流率自由现金流/营收 | 9.9% | — |
| 资本支出强度资本支出/营收 | 1.5% | — |
| 现金转化率经营现金流/净利润 | 1.50× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $205.3M | — |
8季度趋势，按日历期对齐
经营现金流CVCORPRX
| Q4 25 | $66.1M | $827.1M | ||
| Q3 25 | $78.5M | $702.6M | ||
| Q2 25 | $55.5M | $364.0M | ||
| Q1 25 | $38.6M | $596.1M | ||
| Q4 24 | $37.8M | $742.5M | ||
| Q3 24 | $54.7M | $703.6M | ||
| Q2 24 | $47.4M | $658.2M | ||
| Q1 24 | — | $664.6M |
自由现金流CVCORPRX
| Q4 25 | $57.6M | — | ||
| Q3 25 | $68.7M | — | ||
| Q2 25 | $46.4M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $32.3M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $42.4M | — | ||
| Q1 24 | — | — |
自由现金流率CVCORPRX
| Q4 25 | 9.9% | — | ||
| Q3 25 | 12.4% | — | ||
| Q2 25 | 8.3% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 6.2% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 8.9% | — | ||
| Q1 24 | — | — |
资本支出强度CVCORPRX
| Q4 25 | 1.5% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | — | — |
现金转化率CVCORPRX
| Q4 25 | 1.50× | 3.86× | ||
| Q3 25 | 1.50× | 2.44× | ||
| Q2 25 | 1.08× | 12.06× | ||
| Q1 25 | 1.06× | 2.50× | ||
| Q4 24 | 0.67× | 3.57× | ||
| Q3 24 | 1.25× | 1.29× | ||
| Q2 24 | 1.38× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVCO
| Manufactured Product Other | $532.5M | 92% |
| Other | $26.0M | 4% |
| Financial Service Other | $20.5M | 4% |
| Insurance Agency Commissions | $2.0M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
